UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals
In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL), and raised its price target from $14.00 to $21.00.
Jefferies noted, “RIGL reported 3Q12 earnings. RIGL continues to expect OSKIRA-4 Phase 2b results for fostamatinib (R788) in rheumatoid arthritis by YE2012 and OSKIRA-1-3 results in 1H13. We continue to believe in long-term upside for RIGL shares given the potential for fostamatinib and are increasing our estimates for the higher-than expected Xeljanz (oral competitor) pricing.”
Rigel Pharmaceuticals closed on Tuesday at $8.76.
Latest Ratings for RIGL
|Jun 2013||Piper Jaffray||Downgrades||Overweight||Neutral|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.